GlobeNewswire by notified

Vaccinologists Keith Klugman and Shabir Madhi Awarded Sabin’s Prestigious Gold Medal; Infectious Diseases Epidemiologist Nicole Basta Receives Rising Star Award

Share

WASHINGTON, April 19, 2024 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute yesterday presented the Albert B. Sabin Gold Medal to physician-researchers Keith Paul Klugman and Shabir Ahmed Madhi, and its Rising Star award to infectious diseases epidemiologist Nicole Elaine Basta at a ceremony in the National Academy of Sciences building in Washington D.C.

Klugman and Madhi received the Sabin Gold Medal, one of the highest recognitions for vaccinologists globally, for their seminal combined contributions to the development of vaccines against pneumonia and diarrheal disease – major causes of death in children in low- and middle-income countries (LMICs). Klugman first met his then-graduate student Madhi at South Africa’s University of the Witwatersrand (also known as Wits University), where Klugman established, and Madhi expanded, a now globally renowned infectious diseases research institute. Apart from pneumonia, their work focused on maternal and children’s vaccines including influenza, respiratory syncytial virus (RSV), typhoid, and Group B streptococcus (GBS).

The evidence produced by these two awardees has and continues to inform the World Health Organization’s recommendations for vaccines. Klugman and Madhi’s research has helped pave the way for the introduction of lifesaving vaccines in public immunization programs – including the pneumococcal conjugate vaccine where their findings were pivotal in influencing vaccination policy in many LMICs.

“I am honored to award the Sabin Gold Medal to Dr. Klugman and Dr. Madhi for their extraordinary work on vaccines that have saved lives in communities most in need of these interventions,” says Amy Finan, Sabin’s chief executive officer. “Their pneumonia research has been particularly transformative in shaping our understanding of the disease and strengthening global health strategies to protect children from this vaccine-preventable disease.”

Fueled by an early interest in science as a child in South Africa -- in part due to a physician father – Klugman holds both a medical as well as a science doctorate degree from Wits University and was the first student in the school’s history to obtain them simultaneously. He began his research career nearly five decades ago investigating the typhoid vaccine and has since distinguished himself as a formidable infectious diseases’ scientist. Klugman is widely known for his work on pneumonia, which still kills a child under five every 43 seconds, many in the world’s poorest countries. As the director of the pneumonia program at the Seattle-based Bill and Melinda Gates Foundation, Klugman orchestrates strategic initiatives aimed at reducing deaths from pneumonia, RSV, neonatal sepsis, and meningitis. He has authored hundreds of publications that have been cited over 50,000 times to date and has been elected to the National Academy of Medicine in the United States. Klugman is also a professor emeritus of global health at Atlanta’s Emory University.

His scientific achievements aside, Klugman has long championed the need for the world’s poorest children to have equitable access to vaccines. While in South Africa he joined in Wits University’s struggle to allow access to the institution for all students.

“It is absolutely wonderful to be receiving this award, especially together with Shabir,” he says. “When I look down the list of previous awardees, I recognize the great majority of them, and it is extraordinary to now be numbered among them.”

With a career spanning more than 25 years, Madhi, also from South Africa, is a trained pediatrician whose research continues to be instrumental in prioritizing the rollout of vital vaccines and guiding global public health policies. At Wits University, he led clinical trials focused on respiratory and meningeal pathogens, including vaccines targeted at pregnant women and their unborn babies. Madhi led the first study showing that a rotavirus vaccine could significantly prevent severe diarrhea during the first year of life in African infants. That research served as a key piece of evidence for the WHO’s recommendation of universal rotavirus vaccination. In addition, he also led the first two COVID-19 vaccine trials in Africa, and a number of COVID-19 epidemiology studies which led to the first evidence suggesting that infection-induced immunity and vaccinations played a role in reducing severity of disease.

Madhi heads South Africa’s widely respected South African Medical Research Council (SAMRC) Vaccines and Infectious Diseases Analytics Research Unit (Wits VIDA) and is a professor of vaccinology at Wits. He too has co-authored hundreds of publications which have been cited over 59,000 times. Madhi is a recipient of numerous lifetime achievement awards in South Africa, as well being bestowed an Honorary Commander of the Order of the British Empire (CBE) from the British Government for his services to science and public health in a global pandemic.

“It is really humbling for me to be acknowledged for my contributions in the field of vaccinology along with those who have received the Gold Medal award,” says Madhi. “It makes me realize that the work my team and I have done is acknowledged by my peers as being of substance. Most significantly, we contributed to protecting lives in those settings where a majority of death and suffering occurs, and that is in LMICs.”

Sabin’s 2024 Rising Star Nicole Basta, an associate professor at Canada’s McGill University and Canada Research Chair in Infectious Disease Prevention, has led numerous studies to evaluate the impact of vaccines and vaccination programs for a number of globally challenging viral and bacterial diseases, including COVID-19, meningococcal disease, influenza, and HPV.

Inspired by her parents’ emphasis on the importance of education, Basta is a first-generation college graduate who earned an undergraduate degree at Princeton University and graduate degrees at the University of Cambridge and the University of Washington. She has distinguished herself as a prolific researcher with a focus on assessing the impact of vaccination programs and increasing vaccine awareness, acceptance, and uptake. She designed and led studies to evaluate the impact of the meningococcal A vaccine MenAfriVac in Mali and the meningococcal B vaccine Bexsero in the US, both of which contributed to better understanding about how to best implement vaccination programs. In 2020, she and a colleague developed an interactive online COVID-19 vaccine tracker, providing real-time updates to millions of users around the world on the pandemic vaccine development progress.

“Prof. Basta’s impactful and policy-shaping epidemiological research benefits from her ability to make it accessible and useful to the global health community. The COVID-19 vaccine tool is one such instance,” says Finan. “Those achievements alone would make her deserving of the Rising Star but there’s more: she also demonstrates a deep commitment to mentoring the next generation of public health researchers through her research group which is exactly the kind of emerging leader we need.”

Once an infectious diseases outbreak investigator with the Florida Department of Health, Basta has first-hand knowledge that scientific research needs to be understood and adopted beyond the confines of academia. She works with policy makers and public health agencies and organizations to translate research findings into actionable strategies for disease prevention and control.

“It’s truly an honor to receive the 2024 Rising Star Award from the Sabin Vaccine Institute, especially since I am deeply committed to ensuring that we have the evidence we need to demonstrate the importance of vaccination and increase access and uptake,” says Basta. “This recognition is also a testament to the outstanding collaborators and trainees I have had the privilege to work with and it motivates us to continue to make a difference in the years ahead.”

The Gold Medal is Sabin’s highest scientific honor. It has been given annually for more than three decades to a distinguished member of the global health community who has made exceptional contributions to vaccinology or a complementary field. Past award recipients include leaders of vaccinology and vaccine advocacy such as Drs. Barney Graham, Carol Baker, Bill Foege, Anne Gershon, Stanley Plotkin, and Kathrin Jansen.

Sabin’s Rising Star award was created in 2020 to encourage and recognize the next generation of vaccine and immunization leaders.

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with three decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on Twitter, @SabinVaccine.

Media Contact:
Monika Guttman
Senior Media Relations Specialist
Sabin Vaccine Institute
+1 (202) 662-1841
press@sabin.org

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/44d4ebd3-50bb-4e77-846d-0bad4accb05b

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Shareholders approve all resolutions on the agendas of Tenaris’s Annual General Meeting and Extraordinary General Meeting of Shareholders1.5.2024 23:10:26 CEST | Press release

LUXEMBOURG, May 01, 2024 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) announced that its annual general meeting of shareholders and its extraordinary general meeting of shareholders, both held on April 30, 2024, approved all resolutions on their agendas. Among other resolutions adopted at the annual general meeting, shareholders acknowledged the Company’s 2023 annual report, containing the consolidated management report and the related management certifications and external auditors’ reports, and the Company’s 2023 annual sustainability report, containing the non-financial statement required by Luxembourg law. The shareholders also approved the consolidated financial statements as of and for the year ended December 31, 2023, and the annual accounts as at December 31, 2023. The annual general meeting also approved an annual dividend of US$0.60 per share (or US$1.20 per ADR), which represents an aggregate sum of approximately US$0.7 billion, and which include

CNH is changing its NYSE ticker symbol to “CNH” on May 201.5.2024 22:30:00 CEST | Press release

Basildon, May 1, 2024 CNH Industrial (NYSE: CNHI) announces that the Company’s common shares listed on the New York Stock Exchange (NYSE) will begin trading under the symbol “CNH” effective Monday, May 20, 2024. This will replace the Company’s current ticker symbol, “CNHI”, marking a return to both our original ticker symbol “CNH” – used until 2013 – and our identity as a leading pureplay provider of equipment, technology and services for agriculture and construction. CNH Industrial N.V. will remain the name of the legal entity. The ticker symbol for the Company’s 3.850% Notes due 2027 will also change from “CNHI 27” to “CNH 27” at the same time. No action is required by the Company's shareholders or bondholders with respect to the ticker symbol changes, as the Company’s common stock and notes will continue to be listed on the NYSE and their CUSIP numbers will remain unchanged. CNH Industrial (NYSE: CNHI) is a world-class equipment and services company. Driven by its purpose of Breakin

Koelis Announces New Product Release at AUA 2024 to Offer Innovative AI-Enhanced MRI Fusion Biopsy Workflow1.5.2024 20:48:50 CEST | Press release

GRENOBLE, France and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a leader and innovator in prostate care, announced today the release of new features at the prestigious American Urological Association Annual Meeting in San Antonio, TX. Koelis will be holding live and interactive demos at its booth #951 from May 2nd to May 5th to demonstrate its novel capacity integrating AI-enhanced prostate MRI features into its exclusive Trinity platform. The Koelis Trinity® system enables urologists to perform 3D targeted “fusion biopsy” in prostate cancer. Trinity integrates 3D ultrasound imaging with proprietary MRI-US fusion image guidance that features the Company’s unique prostate motion tracking software (OBT Fusion®). The compact Koelis Trinity® system does not require interfaces with either external ultrasound equipment or external sensors. The versatility of the Trinity platform is enabling Koelis to lead the ongoing paradigm sh

Awilco Drilling Plc: Keppel denied leave to appeal the ruling of the AR2 arbitration tribunal1.5.2024 20:34:14 CEST | Press release

Further to the stock exchange releases of 23 November 2023 and 15 January 2024 from Awilco Drilling PLC ("Awilco Drilling") regarding the termination of the newbuilding contract between Awilco Rig 2 Pte. Ltd. ("AR2") and Keppel FELS Limited ("KFELS") for the construction of a semi-submersible drilling rig, hull number B382. The Company has today received the decision of the High Court refusing Keppel’s application for leave to appeal the award of the AR2 arbitration tribunal. The award is in AR2's favour in an amount of USD 43.0 million plus interest and legal costs. Unless the parties can mutually agree, the tribunal will issue a further award related to interest and costs. We will revert once the award has been received and the amounts of interest and costs have been determined. Aberdeen, 1 May 2024 For further information please contact: Eric Jacobs, CEO of Awilco Drilling PLC Phone: +47 9529 2271 Cathrine Haavind, Investor Relations of Awilco Drilling PLC Phone: +47 9342 8464 Email

Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond1.5.2024 18:00:00 CEST | Press release

Ad hoc announcement pursuant to Art. 53 LR The proposed consent fee will be increased to 8’000’000 Idorsia shares. All other matters as proposed on April 23, 2024, remain unchanged.The bondholder meeting will take place on May 6, 2024, in order to vote on the proposals published on April 23, 2024. Allschwil, Switzerland – May 1, 2024 Idorsia Ltd (SIX: IDIA) today announced that in relation to the bondholder meeting for holders of its outstanding convertible bonds maturing on July 17, 2024 (ISIN: CH0426820350) (the Bonds), Idorsia has improved the consent fee to 8’000’000 Idorsia shares up from 5’000’000. Other elements of the proposal published on April 23, 2024 such as the (i) amendment to the conversion price to CHF 6.00 (from currently CHF 33.95), (ii) extension of the maturity date by six months to January 17, 2025 and (iii) giving Idorsia the option to call the Bonds at par, in full or in part, at any time upon giving ten trading days' notice, remain unchanged. Bondholders can acc

HiddenA line styled icon from Orion Icon Library.Eye